Combination of dry extract of Rhodiola, dry extract of Tribulus terrestris, dry extract of Undaria pinnatifida, Moringa oleifera, folic acid and vitamin B12 in the form of food supplement for mitigating woman's disorders caused by ageing.

The present invention relates to a pharmaceutical composition and a health functional food composition, which include phloroglucinol active ingredient, for preventing, treating, or ameliorating somnipathy and suppressing intolerance to, alleviating, or ameliorating side effects of an agonist at the benzodiazepine binding site of the GABA-A receptor. The pharmaceutical composition and the food composition rapidly and reliably induce and maintain sleep, prevent repeated awakenings, unalter physiological sleep architecture, are particularly devoid of residual sedative effects, which could impair daytime functioning and cognitive performance, and neither cause side effects nor intolerance to a conventional agonist at the benzodiazepine binding site of the GABA-A receptor despite long-term administration. The pharmaceutical composition uses a reduced amount of the agonist, which may increase the amount of sleep but degrade the quality of sleep to cause various side effects, to alleviate side effects of the agonist or suppress tolerance to the agonist resulting from long-term administration.

The present invention provides compositions and methods for improving the quality of life for a subject, particularly a child, diagnosed with autism spectrum disorder (ASD). In preferred embodiments, a supplement composition comprising natural or naturally-derived ingredients is delivered to a subject in the form of a chocolate bar or other candy alongside administration of an antiviral medication. Advantageously, the composition and methods can improve the immune health of the subject, along with other signs and symptoms associated with ASD, infections and other immunocompromising conditions.

The present invention provides compositions and methods for improving the quality of life for a subject, particularly a child, diagnosed with autism spectrum disorder (ASD). In preferred embodiments, a supplement composition comprising natural or naturally-derived ingredients is delivered to a subject in the form of a chocolate bar or other candy alongside administration of an antiviral medication. Advantageously, the composition and methods can improve the immune health of the subject, along with other signs and symptoms associated with ASD, infections and other immunocompromising conditions.

The present disclosure provides pharmaceutical compositions including a cannabinoid acid ester compound alone or in combination with one or more additional cannabinoid compounds. In some embodiments, the cannabinoid acid ester compound is a tetrahydrocannabinolic acid (THCA) ester. In some embodiments, the cannabinoid acid ester compound is a cannabigerolic (CBGA) acid ester. In some embodiments, the cannabinoid acid ester compound is a cannabinolic (CBNA) acid ester. A variety of therapeutic applications in which the cannabinoid acid ester compounds and pharmaceutical compositions find use are also provided, including combination therapies using cannabinoid acid ester compounds and one or more additional therapeutic agents.

The present disclosure provides pharmaceutical compositions including a cannabinoid acid ester compound alone or in combination with one or more additional cannabinoid compounds. In some embodiments, the cannabinoid acid ester compound is a tetrahydrocannabinolic acid (THCA) ester. In some embodiments, the cannabinoid acid ester compound is a cannabigerolic (CBGA) acid ester. In some embodiments, the cannabinoid acid ester compound is a cannabinolic (CBNA) acid ester. A variety of therapeutic applications in which the cannabinoid acid ester compounds and pharmaceutical compositions find use are also provided, including combination therapies using cannabinoid acid ester compounds and one or more additional therapeutic agents.

The present disclosure relates to a bioavailable, oil composition wherein at least 20% by weight % of its total lipids content comprises polar lipids such as glycolipids or phospholipids, at least 30 weight % of its polar lipids comprises glycolipids, and no more than 4% by weight % of the oil composition is made up of chlorophyll species. Formulations containing and methods for producing said oil compositions from algal oils or extracts are also disclosed.

The present disclosure relates to a bioavailable, oil composition wherein at least 20% by weight % of its total lipids content comprises polar lipids such as glycolipids or phospholipids, at least 30 weight % of its polar lipids comprises glycolipids, and no more than 4% by weight % of the oil composition is made up of chlorophyll species. Formulations containing and methods for producing said oil compositions from algal oils or extracts are also disclosed.

The invention relates to a nutritional composition for infants and young children comprising proteins, carbohydrates and lipids, wherein said proteins comprise ionic complexes of lactoferrin with acid milk proteins, said complexes having a negative charge at the pH of the infant formula. The nutritional composition is used for providing a satiety feeling and/or a better sleep and/or limiting nocturnal awaking in infants or young children.

The invention relates to a nutritional composition for infants and young children comprising proteins, carbohydrates and lipids, wherein said proteins comprise ionic complexes of lactoferrin with acid milk proteins, said complexes having a negative charge at the pH of the infant formula. The nutritional composition is used for providing a satiety feeling and/or a better sleep and/or limiting nocturnal awaking in infants or young children.